304 related articles for article (PubMed ID: 21673345)
1. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.
Ochi T; Fujiwara H; Okamoto S; An J; Nagai K; Shirakata T; Mineno J; Kuzushima K; Shiku H; Yasukawa M
Blood; 2011 Aug; 118(6):1495-503. PubMed ID: 21673345
[TBL] [Abstract][Full Text] [Related]
2. Antileukemia multifunctionality of CD4(+) T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer.
Fujiwara H; Ochi T; Ochi F; Miyazaki Y; Asai H; Narita M; Okamoto S; Mineno J; Kuzushima K; Shiku H; Yasukawa M
Leukemia; 2015 Dec; 29(12):2393-401. PubMed ID: 26104661
[TBL] [Abstract][Full Text] [Related]
3. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR.
Okamoto S; Mineno J; Ikeda H; Fujiwara H; Yasukawa M; Shiku H; Kato I
Cancer Res; 2009 Dec; 69(23):9003-11. PubMed ID: 19903853
[TBL] [Abstract][Full Text] [Related]
4. Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.
Ochi T; Nakatsugawa M; Chamoto K; Tanaka S; Yamashita Y; Guo T; Fujiwara H; Yasukawa M; Butler MO; Hirano N
Cancer Immunol Res; 2015 Sep; 3(9):1070-81. PubMed ID: 25943533
[TBL] [Abstract][Full Text] [Related]
5. Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice.
Najima Y; Tomizawa-Murasawa M; Saito Y; Watanabe T; Ono R; Ochi T; Suzuki N; Fujiwara H; Ohara O; Shultz LD; Yasukawa M; Ishikawa F
Blood; 2016 Feb; 127(6):722-34. PubMed ID: 26702062
[TBL] [Abstract][Full Text] [Related]
6. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells.
Xue SA; Gao L; Hart D; Gillmore R; Qasim W; Thrasher A; Apperley J; Engels B; Uckert W; Morris E; Stauss H
Blood; 2005 Nov; 106(9):3062-7. PubMed ID: 16020516
[TBL] [Abstract][Full Text] [Related]
7. Transduction of a novel HLA-DRB1*04:05-restricted, WT1-specific TCR gene into human CD4+ T cells confers killing activity against human leukemia cells.
Katsuhara A; Fujiki F; Aoyama N; Tanii S; Morimoto S; Oka Y; Tsuboi A; Nakajima H; Kondo K; Tatsumi N; Nakata J; Nakae Y; Takashima S; Nishida S; Hosen N; Sogo S; Oji Y; Sugiyama H
Anticancer Res; 2015 Mar; 35(3):1251-61. PubMed ID: 25750272
[TBL] [Abstract][Full Text] [Related]
8. HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells.
Lin Y; Fujiki F; Katsuhara A; Oka Y; Tsuboi A; Aoyama N; Tanii S; Nakajima H; Tatsumi N; Morimoto S; Tamanaka T; Tachino S; Hosen N; Nishida S; Oji Y; Kumanogoh A; Sugiyama H
J Immunother; 2013 Apr; 36(3):159-70. PubMed ID: 23502763
[TBL] [Abstract][Full Text] [Related]
9. [Cytotoxicity of T cells transduced with WT1 peptide-specific T-cell receptor gene against human lung cancer cells in vitro].
An J; Cai SW; Li Y; Zhang J
Nan Fang Yi Ke Da Xue Xue Bao; 2014 Aug; 34(9):1319-23. PubMed ID: 25263367
[TBL] [Abstract][Full Text] [Related]
10. An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells.
Kondo K; Fujiki F; Nakajima H; Yatsukawa E; Morimoto S; Tatsumi N; Nishida S; Nakata J; Oka Y; Tsuboi A; Hosen N; Oji Y; Sugiyama H
J Immunother; 2016 Apr; 39(3):127-39. PubMed ID: 26938946
[TBL] [Abstract][Full Text] [Related]
11. Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptor.
Tamanaka T; Oka Y; Fujiki F; Tsuboi A; Katsuhara A; Nakajima H; Hosen N; Nishida S; Lin YH; Tachino S; Akatsuka Y; Kuzushima K; Oji Y; Kumanogoh A; Sugiyama H
Anticancer Res; 2012 Dec; 32(12):5201-9. PubMed ID: 23225417
[TBL] [Abstract][Full Text] [Related]
12. T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing.
Zhou Q; Schneider IC; Edes I; Honegger A; Bach P; Schönfeld K; Schambach A; Wels WS; Kneissl S; Uckert W; Buchholz CJ
Blood; 2012 Nov; 120(22):4334-42. PubMed ID: 22898597
[TBL] [Abstract][Full Text] [Related]
13. T-cell receptor gene therapy of established tumors in a murine melanoma model.
Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
[TBL] [Abstract][Full Text] [Related]
14. Generation of V α13/β21+T cell specific target CML cells by TCR gene transfer.
Zha X; Xu L; Chen S; Yang L; Zhang Y; Lu Y; Yu Z; Li B; Wu X; Zheng W; Li Y
Oncotarget; 2016 Dec; 7(51):84246-84257. PubMed ID: 27713165
[TBL] [Abstract][Full Text] [Related]
15. T cell receptor gene-modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft-versus-host disease.
Okada S; Muraoka D; Yasui K; Tawara I; Kawamura A; Okamoto S; Mineno J; Seo N; Shiku H; Eguchi S; Ikeda H
Cancer Sci; 2023 Nov; 114(11):4172-4183. PubMed ID: 37675556
[TBL] [Abstract][Full Text] [Related]
16. Aurora kinase A-specific T-cell receptor gene transfer redirects T lymphocytes to display effective antileukemia reactivity.
Nagai K; Ochi T; Fujiwara H; An J; Shirakata T; Mineno J; Kuzushima K; Shiku H; Melenhorst JJ; Gostick E; Price DA; Ishii E; Yasukawa M
Blood; 2012 Jan; 119(2):368-76. PubMed ID: 22025529
[TBL] [Abstract][Full Text] [Related]
17. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
[TBL] [Abstract][Full Text] [Related]
18. WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells.
Stauss HJ; Thomas S; Cesco-Gaspere M; Hart DP; Xue SA; Holler A; King J; Wright G; Perro M; Pospori C; Morris E
Blood Cells Mol Dis; 2008; 40(1):113-6. PubMed ID: 17855129
[TBL] [Abstract][Full Text] [Related]
19. Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice.
Xue SA; Gao L; Thomas S; Hart DP; Xue JZ; Gillmore R; Voss RH; Morris E; Stauss HJ
Haematologica; 2010 Jan; 95(1):126-34. PubMed ID: 19679884
[TBL] [Abstract][Full Text] [Related]
20. A Functionally Superior Second-Generation Vector Expressing an Aurora Kinase-A-Specific T-Cell Receptor for Anti-Leukaemia Adoptive Immunotherapy.
Casey NP; Fujiwara H; Tanimoto K; Okamoto S; Mineno J; Kuzushima K; Shiku H; Yasukawa M
PLoS One; 2016; 11(6):e0156896. PubMed ID: 27271876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
